Navigation Links
A miR boost enables acute leukemia cells to mature
Date:4/3/2009

COLUMBUS, Ohio A new study by Ohio State University cancer researchers shows that boosting the level of a molecule called miR-29b in acute myeloid leukemia (AML) cells can reverse gene changes that trap the cells in an immature, fast growing state of development.

The study discovered how the miR reactivates silenced genes, which enables the leukemic cells to differentiate and mature, important steps that precede their death. The findings suggest that miR-29b could be a potent treatment for AML.

The molecule blocks the action of three enzymes, all of which add small chemical units called methyl groups to genes. The addition of the units locks genes down tight and takes them out of action.

By blocking the enzymes, the miR removes the methyl groups from genes, a process called demethylation, which then reactivates them.

The study is reported online in the journal Blood.

"We show that miR-29b is a powerful demethylating agent and provides a rationale for developing this molecule as a possible drug for the treatment of AML, alone or in combination with other agents," says first author Dr. Ramiro Garzon, a hematologist-oncologist and assistant professor of internal medicine at the Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute.

Garzon notes that the miR might prove to be more potent than current demethylating agents, which block only one of the three enzymes inhibited by miR-29b. "The action of miR-29b is more complete," he says.

Earlier research by the same investigators using lung cancer cells showed that miR-29b targets two enzymes, DNMT3A and DNMT3B, that both add the chemical units (methyl groups) to genes.

When the researchers raised the level of miR-29b in leukemic cells, the amount of a third enzyme, called DNMT1, fell.

"We discovered that this miR blocks DNMT1 also, but indirectly," Garzon says.

The miR, it turns out, targets another protein called Sp1 that boosts production of the DNMT1 protein.

Thus, low levels of the miR may result in lots of Sp1 protein and of DNMT1, which busily adds the chemical units that silences genes. High levels of the miR, on the other hand, may keep the amount of Sp1 low, so there is little DNMT1 and much less gene silencing.

"Our paper explains why this miR is a powerful demethylating agent," Garzon says. "It shows that putting this miR back into leukemia cell lines and leukemia cells from patients causes a drop in global DNA methylation and reactivates protective tumor suppressor genes, which allows the cells to differentiate and mature."


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert  

Related biology news :

1. Therapeutic cloning gets a boost with new research findings
2. Major NSF grant boosts UNH research on hormonal genomics
3. New MegaMatcher Accelerator Boosts Speed for High-Volume Biometric Identification and Database Duplicate Searching
4. High CO2 boosts plant respiration, potentially affecting climate and crops
5. Research project to boost European fish farming
6. A little wine boosts omega-3 in the body: Researchers find a novel mechanism for a healthier heart
7. Tropical forest carbon monitoring gets big boost
8. Shrimp trawling may boost mercury in red snapper, study suggests
9. Supercomputer provides massive computational boost to biomedical research at TGen
10. Boost from McGill, Gates Foundation helps Africans control pharma research
11. Diabetes researcher gets $5M boost
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A miR boost enables acute leukemia cells to mature
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology: